Ketamine for depression: a potential role in requests for Medical Aid in Dying?

IF 2.1 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Nicolas Garel, Michka Nazon, Kamran Naghi, Elena Willis, Karl Looper, Soham Rej, Kyle T Greenway
{"title":"Ketamine for depression: a potential role in requests for Medical Aid in Dying?","authors":"Nicolas Garel, Michka Nazon, Kamran Naghi, Elena Willis, Karl Looper, Soham Rej, Kyle T Greenway","doi":"10.1097/YIC.0000000000000462","DOIUrl":null,"url":null,"abstract":"<p><p>Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and primarily involve mood disorders as the primary condition. Nevertheless, MAiD for psychiatric disorders is associated with significant controversy and debate, especially regarding the definition and determination of irremediability - that a given patient lacks any reasonable prospect for recovery. In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions. To our knowledge, this is the first report of ketamine or any other intervention yielding remission in a patient who would have otherwise likely been eligible for MAiD for depression. We discuss implications for the evaluation of similar requests and, more specifically, why a trial of ketamine warrants consideration.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 5","pages":"352-355"},"PeriodicalIF":2.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YIC.0000000000000462","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and primarily involve mood disorders as the primary condition. Nevertheless, MAiD for psychiatric disorders is associated with significant controversy and debate, especially regarding the definition and determination of irremediability - that a given patient lacks any reasonable prospect for recovery. In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions. To our knowledge, this is the first report of ketamine or any other intervention yielding remission in a patient who would have otherwise likely been eligible for MAiD for depression. We discuss implications for the evaluation of similar requests and, more specifically, why a trial of ketamine warrants consideration.

氯胺酮治疗抑郁症:在申请临终医疗救助中的潜在作用?
临终医疗协助(MAiD)是指医疗服务提供者应病人的要求,在其因严重且无法治愈的疾病而遭受难以忍受的痛苦时结束其生命的行为。在过去的十年中,使用临终关怀的范围不断扩大,最近,在一些国家,精神疾病患者也可以使用临终关怀。最近的研究发现,此类精神病治疗申请正在迅速增加,主要涉及以情绪障碍为主的疾病。尽管如此,精神疾病的 MAiD 仍然存在着巨大的争议和争论,尤其是关于不可救药性的定义和判定--即特定患者缺乏任何合理的康复前景。在这篇文章中,我们报告了一名加拿大患者的病例,她因长期患有严重的难治性抑郁症而积极申请临终医疗协助,直到她从氯胺酮静脉注射疗程中获得了显著的疗效。据我们所知,这是第一份关于氯胺酮或任何其他干预措施使抑郁症患者病情缓解的报告,如果没有氯胺酮或其他干预措施,该患者很可能因抑郁症而符合临终医疗协助的条件。我们讨论了对类似请求进行评估的意义,更具体地说,为什么需要考虑进行氯胺酮试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.40
自引率
23.10%
发文量
97
审稿时长
>12 weeks
期刊介绍: International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology. It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes. A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology. To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV. Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信